Comments
Drug maker Hetero has received approval for the generic version of Sofosbuvir and Velpatasvir combination drug from the Drug Controller-General of India.
The approved drug is a generic of Gilead’s Epclusa brand and is indicated for the treatment of chronic Hepatitis C genotype 1 to 6, the Hyderabad-based Hetero said in a release issued here on Friday.
It will be distributed and marketed in the domestic market under the brand 'Velasof’ by Hetero Healthcare.
"This product will be launched under a non-exclusive agreement with Gilead Science Inc, which allows it to manufacture and sell generic versions of its chronic Hepatitis C medicines in 101 developing countries,’’ the company said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.